# Phase 2 endometrial cancer trials recruiting: 75 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 75 trials in phase 2 for endometrial cancer that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 endometrial cancer trials: 75 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/endometrial-neoplasms

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 75
- Recruiting or not yet: 75
- Read on: November 19, 2026

## Trials

The 25 newest of 75, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 16, 2026 | NCT07940062 | Co-Existent Endometrial and Ovarian Carcinoma: Molecular Stratification for Pathologic Reporting and Clinical Management | British Columbia Cancer Agency | Phase 2 | Not yet recruiting | Co-existent Endometrial and Ovarian Carcinoma, Ovarian Carcinoma, Endometrial Carcinoma (EC) | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07940062) |
| October 28, 2026 | NCT07900256 | A Preliminary Exploratory Study of Cadonilimab Combined With Progestin for Fertility-Sparing Treatment in Early Endometrial Cancer | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Phase 2 | Not yet recruiting | Endometrial Cancer | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07900256) |
| September 21, 2026 | NCT07832227 | Imlunestrant/Abemaciclib/Selinexor in Ovarian and Endometrial | Dana-Farber Cancer Institute | Phase 2 | Not yet recruiting | Low Grade Ovarian Serous Adenocarcinoma, Endometrial Cancer | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07832227) |
| September 15, 2026 | NCT07820358 | Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer | The Methodist Hospital Research Institute | Phase 2 | Not yet recruiting | Endometrial Atypical Hyperplasia, Endometrial Atypical Hyperplasia/Endometrioid Intraepithelial Neoplasia, Endometrial... | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07820358) |
| August 28, 2026 | NCT07793318 | TR115 in ARID1A-Mutated Advanced Solid Tumors | Tarapeutics Science Inc. | Phase 2 | Not yet recruiting | Ovarian Clear Cell Carcinoma, Endometrial Cancer, Stomach Cancer Recurrent, Urinary Bladder Cancer | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07793318) |
| August 24, 2026 | NCT07781150 | Mazdutide Plus LNG-IUS for Fertility-Sparing Treatment of AEH or Early Endometrial Cancer | Tongji Hospital | Phase 2 | Not yet recruiting | Obesity, Overweight, Atypical Endometrial Hyperplasia, Endometrial Carcinoma Stage I, Endometrioid Endometrial Cancer | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07781150) |
| July 31, 2026 | NCT07738315 | Elemene Liposomes in Endometrial Cancer | Women's Hospital School Of Medicine Zhejiang University | Phase 2 | Not yet recruiting | Endometrial Carcinoma | 212 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07738315) |
| July 30, 2026 | NCT07737795 | Evaluating the Addition of OK-1 Weekly Paclitaxel in Patients With Endometrial Cancer | University of Oklahoma | Phase 2 | Recruiting | Endometrial Cancer | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07737795) |
| July 28, 2026 | NCT07731607 | Sintilimab Monotherapy in Patients With Stage I-II MSI-H/dMMR Endometrial Cancer | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | MMRd Endometrial Cancer of Stage I~II | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07731607) |
| July 20, 2026 | NCT07714070 | Orlistat Plus Progestin for Fertility-Sparing Treatment of Endometrial Cancer or Atypical Hyperplasia | Peking University People's Hospital | Phase 2 | Not yet recruiting | Endometrial Neoplasms, Endometrial Cancer, Atypical Endometrial Hyperplasia, Progestin Resistance | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07714070) |
| June 9, 2026 | NCT07634601 | Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial Cancer | Jonsson Comprehensive Cancer Center | Phase 2 | Not yet recruiting | Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma, Recurrent Endometrial Carcinoma, Stage III... | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07634601) |
| June 8, 2026 | NCT07631884 | Exploratory Study on the Efficacy and Safety of Trastuzumab Rezetecan in the Treatment of HER2-Expressiong Advanced Solid Tumor | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Solid Tumors, Neoplasms (Cancer / Tumors), Advanced Malignant Solid Neoplasm, Locally Advanced Malignant Solid... | 15 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07631884) |
| June 8, 2026 | NCT07631871 | An Exploratory Study of Zanidatamab in HER2-positive Advanced Tumor After at Least One Line of Standard Therapy | Sponsor not shown (see the record) | Phase 2 | Not yet recruiting | Neoplasms, Solid Tumors, HER2 Positive Solid Tumor, Endometrial Neoplasm, Urothelial Carcinoma (UC), Pancreatic... | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07631871) |
| May 22, 2026 | NCT07605247 | Tirzepatide in the Treatment of Endometrial Cancer | Rutgers, The State University of New Jersey | Phase 2 | Not yet recruiting | Endometrial Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07605247) |
| May 18, 2026 | NCT07594015 | Pembrolizumab and Lenvatinib in Mismatch Repair Proficient Recurrent Endometrial Cancer After Progression on or Following First-Line... | University of Miami | Phase 2 | Recruiting | Recurrent Endometrial Cancer | 46 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07594015) |
| May 14, 2026 | NCT07586826 | Romiplostim N01 Plus ATRA for Persistent Isolated Chemotherapy-Induced Thrombocytopenia After Complete Remission of Gynecologic, Breast, or... | Peking University People's Hospital | Phase 2 | Recruiting | Persistent Isolated Chemotherapy-Induced Thrombocytopenia, Chemotherapy-Induced Thrombocytopenia, Gynecologic Cancers... | 220 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07586826) |
| April 13, 2026 | NCT07522697 | Inavolisib for PIK3CA Mutated Advanced Endometrial Cancer: MITO END-4 | National Cancer Institute, Naples | Phase 2 | Not yet recruiting | Endometrial Cancer | 48 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07522697) |
| April 7, 2026 | NCT07516210 | Adaptive Radiotherapy for Safe Hypofractionation | Centre hospitalier de l'Université de Montréal (CHUM) | Phase 2 | Not yet recruiting | Cancer, Endometrial Cancer, Prostate Cancer, Cervical Cancer, Rectal Cancers | 264 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07516210) |
| March 3, 2026 | NCT07446049 | A Single-arm, Open-label, Multicenter, Phase Ib/II Clinical Trial of CVL237 Tablets in Combination With Serplulimab Injection for the... | Convalife (Shanghai) Co., Ltd. | Phase 2 | Not yet recruiting | Locally Advanced or Metastatic Solid Tumors, PTEN Loss or Low Expression | 180 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07446049) |
| January 30, 2026 | NCT07377734 | Intrauterine Injection of Type III Collage in FST of EC/AEH | Sponsor not shown (see the record) | Phase 2 | Recruiting | Atypical Endometrial Hyperplasia, Endometrial Cancer | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07377734) |
| January 27, 2026 | NCT07369986 | Immunotherapy for Surgery Avoidance in Vulnerable dMMR Endometrial Cancer | Women's Hospital School Of Medicine Zhejiang University | Phase 2 | Not yet recruiting | Endometrial Cancer, Immunotherapy, Mismatch Repair Deficiency | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07369986) |
| December 16, 2025 | NCT07285044 | The Cancer Connected Access and Remote Expertise Beyond Walls Program to Provide In-Home Cancer Treatment and Improve Treatment... | Mayo Clinic | Phase 2 | Recruiting | Amyloidosis, Basal Cell Carcinoma, Biliary Tract Carcinoma, Bladder Carcinoma, Breast Carcinoma, Cervical Carcinoma... | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07285044) |
| October 7, 2025 | NCT07209449 | A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | Endometrial Cancer | 75 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07209449) |
| September 12, 2025 | NCT07170982 | Fruquintinib Combined With Standard Chemotherapy Versus Standard Chemotherapy as First-line Treatment for Advanced pMMR Endometrial Cancer | Sun Yat-sen University | Phase 2 | Not yet recruiting | Endometrial Cancer | 128 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07170982) |
| August 24, 2025 | NCT07139977 | Study of EV for Recurrent Endometrial Carcinoma | Sponsor not shown (see the record) | Phase 2 | Recruiting | Endometrial Cancer | 12 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07139977) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Dana-Farber Cancer Institute | 4 |
| Peking University People's Hospital | 4 |
| Memorial Sloan Kettering Cancer Center | 4 |
| National Cancer Institute (NCI) | 3 |
| Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | 2 |
| Jonsson Comprehensive Cancer Center | 2 |
| Sun Yat-sen University | 2 |
| Convalife (Shanghai) Co., Ltd. | 2 |
| Women's Hospital School Of Medicine Zhejiang University | 2 |
| Fudan University | 2 |
| Aadi Bioscience, Inc. | 1 |
| Tarapeutics Science Inc. | 1 |
| Iovance Biotherapeutics, Inc. | 1 |
| University of Oklahoma | 1 |
| Mayo Clinic | 1 |
| The Methodist Hospital Research Institute | 1 |
| Rutgers, The State University of New Jersey | 1 |
| Shandong University | 1 |
| University of Utah | 1 |
| Washington University School of Medicine | 1 |
| Tianjin Medical University Cancer Institute and Hospital | 1 |
| [GlaxoSmithKline](https://specstream.ai/data/clinical-trials/company/glaxosmithkline) | 1 |
| Canadian Cancer Trials Group | 1 |
| British Columbia Cancer Agency | 1 |
| Acrivon Therapeutics | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 35 |
| China | 26 |
| Canada | 8 |
| Italy | 7 |
| South Korea | 7 |
| France | 6 |
| Spain | 6 |
| Australia | 5 |
| Germany | 5 |
| Japan | 3 |
| Netherlands | 2 |
| Norway | 2 |
| Belgium | 2 |
| Poland | 2 |
| Switzerland | 2 |
| Taiwan | 2 |
| United Kingdom | 2 |
| New Zealand | 1 |
| Turkey (Türkiye) | 1 |
| Puerto Rico | 1 |
| Georgia | 1 |
| Hungary | 1 |
| Denmark | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Executive search firms in the United States](https://specstream.ai/data/businesses/executive-search-firms/united-states)
- [Indian restaurants in the United States](https://specstream.ai/data/businesses/indian-restaurants/united-states)
- [Nepalese restaurants in the United States](https://specstream.ai/data/businesses/nepalese-restaurants/united-states)
- [Rail services in the United States](https://specstream.ai/data/businesses/rail-services/united-states)
- [Tractor dealers in the United States](https://specstream.ai/data/businesses/tractor-dealers/united-states)
- [Auto insurance agencies in the United States](https://specstream.ai/data/businesses/auto-insurance-agencies/united-states)
